“I am happy to welcome Henrik who, with his robust experience and personal qualities will constitute a major asset for Oncopeptides and its leadership,” says Sofia Heigis, CEO of Oncopeptides.
“His more than 20 years of experience from leading finance roles at both medical and non-medical listed companies will be beneficial for us as we continue to build an organisation designed for growth.”